Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Phytase and Reduced WOMAC Pain Score

Doses used in studies

mg/day: 1,600 (median 1,600, IQR 1,600–1,600) — 1 study

Time to effect

Median: 4 weeks · IQR 4 weeks–4 weeks · Range 4 weeks–4 weeks — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityReported
Adverse events (mainly gastrointestinal) were mild to moderate.
from: The efficacy and safety of a fixed-dose combination of apocynin and paeonol, APPA, in symp

1 of 1 paper

The efficacy and safety of a fixed-dose combination of apocynin and paeonol, APPA, in symptomatic knee OA: A double-blind, randomized, placebo-controlled, clinical trial.
- 2024-07
- RCT · n = 152
- Osteoarthritis and cartilage 32(7)
- - Asger R Bihlet
  - Inger Byrjalsen
  - Jeppe R Andersen
  - Alan Reynolds
  - Nicholas Larkins
  - Peter Alexandersen
  - Helene Rovsing
  - Robert Moots
  - Philip G Conaghan
- PubMed: 38697511
- DOI: 10.1016/j.joca.2024.02.948
3 Insights on
- Reduced WOMAC Pain Score
- High evidence
- Large Human Trial
- Clinical
predefined subgroup analyses of subjects with symptoms compatible with nociplastic/neuropathic pain features showed a statistically significant effect of APPA compared to placebo.
Effect
Beneficial
Effect size
Small
Significant
Yes
Dose
800 mg twice daily